Loading resource…

Endocrinology
The advent of incretin therapies has transformed obesity management, particularly in patients with insulin resistance and related complications. Medications such as exenatide, liraglutide, and semaglutide have shown efficacy in weight loss and improving insulin sensitivity. However, with their extensive use, safety concerns, particularly gastrointestinal adverse effects, have emerged. This document aims to provide insights into these adverse effects and their implications for clinical practice.
No account needed